where to inject bpc 157 for meniscus The injection points; I: intraarticular, P: pes anserinus, TT: Where to Inject BPC-157 for
Description
Deficiency can cause numbness, tingling, and cognitive fog
This failed tendon point was fully reversed in all the BPC 157-treated rats, along with recovering muscle-to-bone attachment (Table 1)
Injectable routes carry a particular concern for immunogenicity from peptide aggregation and impurities, and FDA noted the available certificates of analysis for AOD-9604 bulk drug substances did not consistently control for impurities, aggregates, or microbial limits
In 2015, a Phase I clinical trial conducted on 42 healthy volunteers (both sexes, aged 1835 yrs.) was started
